Survival rates from interval cancer in NHS breast screening programme.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Current Strategies to Reducing Interval Breast Cancers: A Systematic Review.Breast cancer (Dove Medical Press) · 2025
   Review
2. Are international differences in breast cancer survival between Australia and the UK present amongst both screen-detected women and non-screen-detected women? survival estimates for women diagnosed in West Midlands and New South Wales 1997-2006.International journal of cancer · 2016
   Article
3. Prognosis in women with interval breast cancer: population based observational cohort study.BMJ (Clinical research ed.) · 2012
   Article
4. High expression of the trefoil protein TFF1 in interval breast cancers.The American journal of pathology · 2001
   Article
5. A study of interval breast cancer within the NHS breast screening programme.Journal of clinical pathology · 2000
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as